Table 1.
The characteristics of included studies.
| Omitted Study | Year | Country | Study Period | Study Design | Survival Analysis |
Sample Size | Cancer Type | Cancer Stage | Treatment | Outcome | Median Follow-Up (Months) | NOS Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeno et al. [16] | 2014 | Japan | 1995–2006 | retrospective | Multivariable | 494 | Gastric cancer | I–IV * (7th UICC) |
OP ± adjuvant therapy | OS | NR | 8 |
| Nakamura et al. [21] | 2015 | Japan | 2001–2012 | retrospective | Multivariable | 139 | Soft tissue sarcoma | Grade 1–3 (FNCLCC) | OP/RT/CT | DSS | 60 | 8 |
| Liu et al. [30] | 2015 | China | 2005–2010 | retrospective | Univariable | 455 | Gastric cancer | I–III | D2 gastrectomy with R0 resection | OS | 25 | 7 |
| Osugi et al. [15] | 2016 | Japan | 2005–2009 | retrospective | Multivariable | 327 | Non-small cell lung cancer | I–III * (7th UICC) |
OP | OS | 65 | 9 |
| Chen et al. [14] | 2017 | China | 2011–2014 | retrospective | Multivariable | 163 | Esophageal cancer | II–Iva (6th AJCC) |
CCRT | OS | NR | 7 |
| Hanai et al. [22] | 2018 | Japan | 2012–2013 | retrospective | Multivariable | 129 | Head and neck cancer | I–IV (7th UICC) |
OP/CCRT | OS | 43.6 | 8 |
| Hirahara et al. [31] | 2020 | Japan | 2010–2017 | retrospective | Univariable | 434 | Gastric cancer | I–IV * (4th JGCTG) |
OP | OS/DSS | NR | 9 |
| Zheng et al. [24] | 2020 | China | 2008–2016 | retrospective | Multivariable | 70 | Neuroblastoma | 1–4 (INSS) | OP ± adjuvant therapy/CT | OS | 53.1 | 9 |
| Hou et al. [23] | 2020 | China | 2000–2016 | retrospective | Multivariable | 454 | Soft tissue sarcoma | I–III (AJCC), Grade 1–3 (FNCLCC) | OP/RT/CT | OS | 94.8 | 9 |
| Ando et al. [25] | 2021 | Japan | 2005–2019 | retrospective | Multivariable | 131 | Castration-resistant prostate cancer | IV | ADT plus docetaxel | OS/PFS | 21.1 | 8 |
| Bao et al. [32] | 2021 | China | 2010–2017 | retrospective | Multivariable | 144 | Gallbladder cancer | I–IV * (8th AJCC) |
OP | OS | NR | 8 |
| Lu et al. [28] | 2021 | China | 2006–2014 | retrospective | Multivariable | 1625 | Hepatocellular carcinoma | ABC (BCLC-C) | TACE | OS | NR | 7 |
| Iuchi et al. [26] | 2021 | Japan | 2009–2020 | retrospective | Multivariable | 106 | Oropharyngeal cancer | I–IV * (8th AJCC) |
OP/CCRT | OS/DFS | 42 | 8 |
| Iuchi et al. [27] | 2021 | Japan | 2007–2019 | retrospective | Multivariable | 115 | Hypopharyngeal cancer | II–IV * (8th AJCC) |
OP/CCRT | OS/DFS | 62 | 8 |
| Nakamura et al. [33] | 2022 | Japan | 2002–2018 | retrospective | Univariable | 144 | Soft tissue sarcoma | Grade 1–3 (FNCLCC) | OP | DSS | 76 | 9 |
| Tsai et al. [7] | 2022 | Taiwan | 2008–2017 | retrospective | Multivariable | 303 | Oral squamous cell carcinoma | I–IV * (8th AJCC) |
OP ± adjuvant therapy | OS/DFS | 40.9 | 9 |
| Kasahara et al. [29] | 2022 | Japan | 2000–2015 | retrospective | Multivariable | 595 | Colorectal cancer | II–IV * | OP ± adjuvant therapy | OS | NR | 7 |
* excluded metastasis. Abbreviations: AJCC, American Joint Committee on Cancer; UICC, Union for International Cancer Control tumor-node-metastasis; FNCLCC, French Federation of Cancer Centers Sarcoma Group grading system; BCLC-C, Barcelona Clinic Liver Cancer-Stage C; JGCTG, Japanese Gastric Cancer Treatment Guidelines; INSS, International Neuroblastoma Staging System; OP, operation; RT, radiotherapy; CT, chemotherapy; ADT, androgen depletion therapy; NR, not reported.